Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

The Effect of Xolair (Omalizumab) on Allergy Blood Cells

This study has been completed.
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Creighton University Identifier:
First received: April 8, 2008
Last updated: September 30, 2013
Last verified: September 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2007
  Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)